Breaking News


Adalimumab for psoriasis patients unresponsive to etanercept


An open-label, prospective trial of five patients with psoriasis unresponsive to etanercept (50 mg twice weekly) enrolled patients to treatment with adalimumab 40 mg/week s.c. for 12 weeks. The primary endpoint was the percentage of patients attaining a 50% or greater decrease in the Psoriasis Area and Severity Index (PASI 50) at week 12. The PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8 and 12. Four out of five patients attained PASI 50 at week 12. Of these, two achieved a PASI 75 score. All patients had an improvement in their DLQI scores and no serious adverse events were reported ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list